TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Information Branches Combined Under ICIC, Moved to Office Of NCI Deputy Director November 23, 1997